L-703,606

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598163

CAS#: 144425-84-3

Description: L-703,606 is a potent, selective antagonist to the human NK1 receptor.

Chemical Structure

img
L-703,606
CAS# 144425-84-3
Instruction

Theoretical Analysis

MedKoo Cat#: 598163
Name: L-703,606
CAS#: 144425-84-3
Chemical Formula: C27H29IN2
Exact Mass: 508.14
Molecular Weight: 508.440
Elemental Analysis: C, 63.78; H, 5.75; I, 24.96; N, 5.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 144425-84-3 (Oxalate)   351351-06-9 (Oxalate hydrate)   144425-84-3  

Synonym: L 703606; L-703606; L703606; L-703,606; L 703,606; L703,606;

IUPAC/Chemical Name: (2R,3R)-2-benzhydryl-N-(2-iodobenzyl)quinuclidin-3-amine

InChi Key: WSLTYZVXORBNLB-KAYWLYCHSA-N

InChi Code: InChI=1S/C27H29IN2/c28-24-14-8-7-13-23(24)19-29-26-22-15-17-30(18-16-22)27(26)25(20-9-3-1-4-10-20)21-11-5-2-6-12-21/h1-14,22,25-27,29H,15-19H2/t26-,27-/m1/s1

SMILES Code: IC1=CC=CC=C1CN[C@H]2[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)N5CCC2CC5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 508.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res. 2012 Mar 1;18(5):1281-90. doi: 10.1158/1078-0432.CCR-11-2892. Epub 2012 Jan 23. PubMed PMID: 22271876; PubMed Central PMCID: PMC3294177.

2: Sasaki K, Yokobayashi S, Nakamura T, Okamoto I, Yabuta Y, Kurimoto K, Ohta H, Moritoki Y, Iwatani C, Tsuchiya H, Nakamura S, Sekiguchi K, Sakuma T, Yamamoto T, Mori T, Woltjen K, Nakagawa M, Yamamoto T, Takahashi K, Yamanaka S, Saitou M. Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells. Cell Stem Cell. 2015 Aug 6;17(2):178-94. doi: 10.1016/j.stem.2015.06.014. Epub 2015 Jul 16. PubMed PMID: 26189426.

3: Tao K, Chen B, Hu DH, Wang BT. [The influence of non-peptide NK1 receptor antagonist L-703, 606 on the early tissue edema formation in rats with deep partial-thickness scald]. Zhonghua Shao Shang Za Zhi. 2005 Dec;21(6):455-8. Chinese. PubMed PMID: 16480633.

4: Mino T, Murakawa Y, Fukao A, Vandenbon A, Wessels HH, Ori D, Uehata T, Tartey S, Akira S, Suzuki Y, Vinuesa CG, Ohler U, Standley DM, Landthaler M, Fujiwara T, Takeuchi O. Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms. Cell. 2015 May 21;161(5):1058-1073. doi: 10.1016/j.cell.2015.04.029. PubMed PMID: 26000482.

5: Hebbard L, Cecena G, Golas J, Sawada J, Ellies LG, Charbono A, Williams R, Jimenez RE, Wankell M, Arndt KT, DeJoy SQ, Rollins RA, Diesl V, Follettie M, Chen L, Rosfjord E, Cardiff RD, Komatsu M, Boschelli F, Oshima RG. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene. 2011 Jan 20;30(3):301-12. doi: 10.1038/onc.2010.412. Epub 2010 Sep 6. PubMed PMID: 20818417; PubMed Central PMCID: PMC3000443.

6: Hashimoto Y, Ohashi R, Kurosawa Y, Minami K, Kaji H, Hayashida K, Narita H, Murata S. Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. J Cardiovasc Pharmacol. 1998 Apr;31(4):568-75. PubMed PMID: 9554806.

7: Roy S, He R, Kapoor A, Forman M, Mazzone JR, Posner GH, Arav-Boger R. Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation. Antimicrob Agents Chemother. 2015 Jul;59(7):3870-9. doi: 10.1128/AAC.00262-15. Epub 2015 Apr 13. PubMed PMID: 25870074; PubMed Central PMCID: PMC4468661.

8: Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 2010 May;9(5):1147-57. doi: 10.1158/1535-7163.MCT-09-0962. Epub 2010 Apr 27. PubMed PMID: 20423991.

9: Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M, Okubo C, Nishikawa M, Oishi A, Narita M, Miyashita I, Asano K, Hayashi K, Osafune K, Yamanaka S, Saito H, Yoshida Y. Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches. Cell Stem Cell. 2015 Jun 4;16(6):699-711. doi: 10.1016/j.stem.2015.04.005. Epub 2015 May 21. PubMed PMID: 26004781.

10: Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008 Feb 15;111(4):2329-38. Epub 2007 Dec 4. PubMed PMID: 18056843; PubMed Central PMCID: PMC2234062.

11: Chikazu D, Shindo M, Iwasaka T, Katagiri M, Manabe N, Takato T, Nakamura K, Kawaguchi H. A novel synthetic triazolotriazepine derivative JTT-606 inhibits bone resorption by down-regulation of action and production of bone resorptive factors. J Bone Miner Res. 2000 Apr;15(4):674-82. PubMed PMID: 10780859.

12: Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, Boghaert E, Arndt K, Ye F, Boschelli DH, Li F, Titsch C, Huselton C, Chaudhary I, Boschelli F. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 2005 Jun 15;65(12):5358-64. PubMed PMID: 15958584.

13: Girard D, Leclercq A, Laurent E, Lecuit M, de Valk H, Goulet V. Pregnancy-related listeriosis in France, 1984 to 2011, with a focus on 606 cases from 1999 to 2011. Euro Surveill. 2014 Sep 25;19(38). pii: 20909. PubMed PMID: 25306879.

14: Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66(23):11314-22. Epub 2006 Nov 17. PubMed PMID: 17114238.

15: Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008 May;7(5):1185-94. doi: 10.1158/1535-7163.MCT-08-0126. PubMed PMID: 18483306; PubMed Central PMCID: PMC2794837.

16: Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007 Feb 15;67(4):1580-8. PubMed PMID: 17308097.

17: Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science. 2014 Jun 6;344(6188):1164-8. doi: 10.1126/science.1252809. PubMed PMID: 24904167.

18: Hamada T, Yasunaga H, Nakai Y, Isayama H, Horiguchi H, Fushimi K, Koike K. Severe bleeding after percutaneous transhepatic drainage of the biliary system: effect of antithrombotic agents--analysis of 34 606 cases from a Japanese nationwide administrative database. Radiology. 2015 Feb;274(2):605-13. doi: 10.1148/radiol.14140293. Epub 2014 Sep 5. PubMed PMID: 25203133.

19: Kashimura T, Hayashi M, Kodama M, Nakazawa M, Abe S, Yoshida T, Tachikawa H, Hanawa H, Kato K, Watanabe K, Aizawa Y. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J. 2003 Sep;44(5):735-44. PubMed PMID: 14587655.

20: Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. PubMed PMID: 16489032.